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Introduction: Continuous renal replacement therapy (CRRT) may alter antibiotic pharmacokinetics and increase
the risk of incorrect dosing. In a nested cohort within a large randomized controlled trial, we assessed the effect
of higher (40 mL/kg per hour) and lower (25 mL/kg per hour) intensity CRRT on antibiotic pharmacokinetics.
Methods: We collected serial blood samples to measure ciprofloxacin, meropenem, piperacillin-tazobactam, and
vancomycin levels. We calculated extracorporeal clearance (CL), systemic CL, and volume of distribution (Vd) by
non-linear mixed-effects modelling. We assessed the influence of CRRT intensity and other patient factors on
antibiotic pharmacokinetics.
Results: We studied 24 patients who provided 179 pairs of samples. Extracorporeal CL increased with higher-intensity
CRRT but the increase was significant for vancomycin only (mean 28 versus 22 mL/minute; P = 0.0003). At any given
prescribed CRRT effluent rate, extracorporeal CL of individual antibiotics varied widely, and the effluent-to-plasma
concentration ratio decreased with increasing effluent flow. Overall, systemic CL varied to a greater extent than Vd,
particularly for meropenem, piperacillin, and tazobactam, and large intra-individual differences were also observed.
CRRT dose did not influence overall (systemic) CL, Vd, or half-life. The proportion of systemic CL due to CRRT varied
widely and was high in some cases.
Conclusions: In patients receiving CRRT, there is great variability in antibiotic pharmacokinetics, which
complicates an empiric approach to dosing and suggests the need for therapeutic drug monitoring. More
research is required to investigate the apparent relative decrease in clearance at higher CRRT effluent rates.
Trial registration: ClinicalTrials.gov NCT00221013. Registered 14 September 2005.Introduction
Bacterial sepsis is common and increases mortality in
critically ill patients with acute kidney injury (AKI) [1].
The administration of antibiotics is a key component of
therapy in these patients [2]. The influence of antibiotic
concentration on bacterial kill has been determined in vitro
and is the basis of current approaches to antibiotic dosing
[3]. Logically, incorrect dosing secondary to a poor under-
standing of pharmacokinetics may contribute to adverse* Correspondence: darren.roberts@uq.edu.au
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of antibiotic resistance [5].
Key aspects of pharmacokinetics like antibiotic clear-
ance (CL) and volume of distribution (Vd) are altered in
critically ill patients with AKI because of loss or renal
clearance, volume expansion, and interventions such as
vasopressors and continuous renal replacement therapy
(CRRT) [6,7]. Moreover, extracorporeal CL during CRRT
is influenced by the physicochemical and pharmacokinetic
properties of the antibiotic, blood flow, dialysate flow, and
ultrafiltration rate and by membrane fouling and filter
clotting [8]. These variables may lead to sub-therapeutic
blood concentrations and contribute to treatment failure
[9-11]. However, data on antibiotic pharmacokineticsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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correct prescription problematic. Accordingly, in patients
treated with CRRT of different intensities, we aimed to
evaluate variability in CL and Vd and to assess the effect
of the CRRT prescription on extracorporeal and systemic
antibiotic CL and Vd.
Methods
Clinical
This was a nested cohort prospective multicenter obser-
vational pharmacokinetic study within a large random-
ized controlled trial of CRRT intensity (trial registration:
ClinicalTrials.gov NCT00221013, registered 14 September
2005) [13]. Inclusion criteria for this study, known as the
Randomized Evaluation of Normal vs. Augmented Level
of CRRT (RENAL) study, have been previously published
and are outlined in the online supplement (Additional
file 1).
In brief, patients were randomly assigned to receive
post-dilutional hemodiafiltration as either a higher
(40 mL/kg body weight/hour effluent flow rate) or
lower (25 mL/kg body weight/hour effluent flow rate)
intensity rate using equal size filters with polyacryloni-
trile membranes. By protocol, the target prescribed
effluent flow was achieved through an equal contribu-
tion of dialysate flow and ultrafiltration. Blood flow was
200 mL/minute for all study patients except two (150
or 180 mL/minute).
Four hospitals in three separate geographical regions
participated in this study. Institutional review boards ap-
proved the study, and informed consent and demographic,
clinical, and laboratory data were obtained [13]; see the
online supplement (Additional file 1) for more details.
Pharmacokinetic sampling occurred at three time points
each day: (1) immediately before antibiotic dosing, (2)
after completion of their intravenous infusion, and (3) at
4 hours after completion of infusion. A patient could
participate on more than one occasion but on different
days. The time of sampling was recorded exactly, and
at each time point, a pre-filter blood sample and CRRT
effluent sample were obtained simultaneously. Plasma
was separated by centrifugation, immediately frozen,
and stored at −70°C until analysis.
Laboratory techniques
The plasma and effluent concentrations of ciprofloxacin
(molecular weight (MW) 331.3), meropenem (MW 383.5),
piperacillin (MW 517.6), and tazobactam (MW 300.3)
were determined by using a validated liquid chromatog-
raphy with tandem mass spectrometry method that has
been described previously [9]; see online supplement
(Additional file 1) for more details. The plasma concentra-
tions of vancomycin (MW 1449.3), urea (MW 60.1), and
creatinine (MW 113.1) were determined by usingcommercial assays by the Chemical Pathology Laboratory,
Princess Alexandra Hospital, Queensland Health Scientific
and Forensic Services, Brisbane, Australia.
Pharmacokinetic calculations
The antibiotic CL from hemodiafiltration (CLHDF) was
calculated at each time point on the basis of drug recovery
in the CRRT effluent by using a standard formula [8,14]:
CLHDF ¼ CE=CPð Þ QE;
where CE is the solute concentration in CRRT effluent, QE
the prescribed CRRT effluent flow, and CP the solute
concentration in plasma. The CE/CP ratio is referred to as
effluent or dialysate saturation [14] or the saturation coef-
ficient (Sd) [8]. The Sd is the diafiltration equivalent of
sieving coefficient, which is calculated in the same way
during hemofiltration. The Sd was also calculated for urea
and creatinine as a measure of filter membrane function.
Using pre-filter plasma concentrations at the three time
points, the systemic CL (CLs) and Vd were calculated.
These time points were chosen so that the first and second
points related to Vd and the second and third related to
CLs. The antibiotic plasma concentration-time data were
fitted to one-, two-, or three-compartment models by
non-linear mixed-effects population modelling (NONMEM
software version 6.1; GloboMax LLC, Hanover, MD, USA)
[15]. A Digital Fortran compiler was used, and runs
were executed by using Wings for NONMEM (WFN)
version 616.
Data were analyzed by using the first-order conditional
estimation method with interaction. Between-subject vari-
ability was calculated by using an exponential variability
model. Residual unexplained variability was tested by
using exponential or additive random error or both. Visual
inspection of diagnostic scatter plots and the NONMEM
objective function value (OFV) were used to evaluate
goodness of fit. Statistical comparison of nested models
was undertaken in the NONMEM program on the basis
of a chi-square test of the difference in OFV. A decrease
in the OFV of 3.84 units (P <0.05) was considered statisti-
cally significant.
The influence of the properties of a given antibiotic
was assessed by using meropenem and vancomycin be-
cause they were the most commonly used antibiotics in
this series and differed in terms of size (MW 438 versus
1,486 Daltons, respectively) and protein binding (less
than 10% versus 30%, respectively [6]).
The systemic elimination half-life (T1/2) was calculated
as follows:
T1=2 ¼ 0:693 Vdð Þ=CLs
The proportion of CLs attributed to hemodiafiltration
was calculated by:
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In the case of CLHDF being determined on multiple
occasions in the same patient during the time period
when CLs was calculated, %CL was determined by using
the mean CLHDF.
Statistical calculations
Statistical analyses were conducted according to the
normality of data which was determined by using the
D’Agostino and Pearson omnibus normality test. Non-
parametric data were subject to the Mann-Whitney and
Spearman r correlation tests, whereas parametric data
were compared by using the Student t test (with Welch’s
correction when variances were not equal) and Pearson
r correlation test. The goodness of fit (r2) of statistically
significant correlations was determined by using linear
regression. All regressions and statistics were conducted
by using GraphPad Prism version 5.03 for Windows
(GraphPad Software, San Diego, CA, USA), and a P value
of less than 0.05 was considered statistically significant.
Results
Sampling occurred at 179 time points in 24 patients: cip-
rofloxacin (19), meropenem (65), piperacillin-tazobactam
(29), and vancomycin (66). The demographics, baseline
clinical characteristics, and other treatments for the 24
study patients have been presented previously [9]. Briefly,
mean age ± standard deviation was 62 ± 17 years, most
were men (16:8), and mean weight was 82 ± 17 kg.
Thirteen patients were diagnosed with sepsis, and edema
was present in 12 patients. Admission APACHE (Acute
Physiology and Chronic Health Evaluation) III and SOFA
(Sequential Organ Failure Assessment) scores were 103 ±
17 and 11.0 ± 3.0, respectively. Ventilatory support was
required in 75% of patients, and 90-day mortality was
42%. The serum creatinine concentration at random-
ization was 273 ± 123 μmol/L, and oligo-anuria was
present in eight patients. The prescribed effluent flow
rates in the higher- and lower-intensity groups were a
median (interquartile range, IQR) of 2,800 (2,600 to 3,100)
mL/hour and 2,130 (2,000 to 2,375) mL/hour, respectively
(P <0.0001).
Extracorporeal antibiotic removal
The antibiotic pre-filter plasma concentration correlated
with the CRRT effluent concentration for each of the
antibiotics (online supplement Figure S1; see Additional
file 1), and Sd was less than 1.0 in 94% of samples. The
influence of CRRT intensity on antibiotic CLHDF is shown
in Table 1. In general, CLHDF increased with higher-
intensity CRRT, but this effect was significant for vanco-
mycin only (mean 28 versus 22 mL/minute; P = 0.0003,
Student t test). Wide standard deviations or IQRs werenoted in each case (Table 1). A correlation was noted
between the prescribed effluent flow rate and CLHDF for
vancomycin but not for other antibiotics (online supple-
ment Figure S2; see Additional file 1).
The mean CLHDF of meropenem and vancomycin did
not differ significantly: higher intensity 23 ± 13 versus
28 ± 7 mL/minute (P = 0.0610) and lower intensity 22 ± 5
versus 21 ± 9 mL/minute (P = 0.6899), respectively. The
CLHDF of piperacillin was less than that of tazobactam,
such that the median CLHDF ratio of piperacillin to tazo-
bactam was 0.56 (IQR 0.39 to 0.72). The median ratio of
the plasma concentrations of piperacillin to tazobactam
was 14.9 (IQR 10.7 to 23.2, range 7.5 to 41.7). The Sd of
vancomycin and meropenem was not consistently influ-
enced by the albumin concentration or hematocrit (online
supplement Figure S3; see Additional file 1).
Extracorporeal uremic solute removal
Urea CLHDF was significantly higher in the higher-
intensity group (mean 41 ± 14 versus 33 ± 7 mL/minute,
P = 0.0002); the same was observed for creatinine CLHDF
(mean 40 ± 13 versus 31 ± 7 mL/minute, P = 0.0003). A
correlation was noted between the prescribed effluent
flow rate and CLHDF for urea and creatinine (online
supplement Figure S4; see Additional file 1). However,
despite the lack of correlation between effluent flow rate
and creatinine Sd, a negative correlation was noted with
urea Sd and effluent flow rate (Figure 1). Moreover, the
urea and creatinine Sd varied markedly within comparable
effluent flow rates. A significant association between the
Sd of urea, creatinine, meropenem, or vancomycin with
the age of CRRT filter was not observed (online supple-
ment Figure S5; see Additional file 1). A positive and
significant correlation was noted with the Sd of both urea
and creatinine for vancomycin (Figure 2) but not merope-
nem (online supplement Figure S6; see Additional file 1).
Systemic clearance and volume of distribution
The results of the population pharmacokinetic model
development and evaluation are outlined in the online
supplement (Additional file 1). The estimates of CLs and
Vd show that inter-individual differences were signifi-
cant for CLs—coefficient of variation (CV%) 10.0 for
ciprofloxacin and 52.3 for tazobactam—and Vd (CV%
24.9 to 37.8) (Table 2).
The net effect of this variability is shown by using
simulation in the case of meropenem, in which an
approximate dose-response relationship is observed, but
despite a twofold difference in dose, the concentration-
time curves are not clearly separated (Figure 3).
In the case of vancomycin and meropenem, the pre-
scribed CRRT effluent rate did not significantly influence
CLs (online supplement Figure S7; Additional file 1), Vd,
or elimination half-life (data not shown).
Table 1 The effect of continuous renal replacement therapy intensity on extracorporeal antibiotic clearance
Antibiotic Antibiotic clearance, higher intensity Antibiotic clearance, lower intensity P value
Ciprofloxacin Median (IQR) 19 (13-24); n = 12 17 (16-20); n = 7 0.5139
Mean (SD) 19 ± 8 17 ± 3
Meropenem Median (IQR) 23 (16-29) 21 (15-28) 0.4802a
Mean (SD) 23 ± 13; n = 35 21 ± 9; n = 28
Piperacillin Median (IQR) 22 (21-31) 24 (17-31) 0.9091a
Mean (SD) 25 ± 10; n = 11 26 ± 12; n = 17
Tazobactam Median (IQR) 37 (34-49) 56 (41-66) 0.0642a,b
Mean (SD) 38 ± 13; n = 11 53 ± 24; n = 17
Vancomycin Median (IQR) 28 (24-33) 21 (19-25) <0.0001a,b
Mean (SD) 28 ± 7; n = 35 22 ± 5; n = 31
aStatistical significance was determined by using the t test because the data were considered normally distributed; the Mann-Whitney test was used for the
remaining analyses. bP <0.05. IQR, interquartile range; SD, standard deviation.
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clearance
The contribution of CLHDF to the calculated CLs also
varied widely. The medians and IQRs were ciprofloxacin
32% (29% to 34%), meropenem 66% (42% to 76%), piper-
acillin 23% (19% to 27%), tazobactam 49% (39% to 57%),
and vancomycin 92% (84% to 109%).
Inter-occasional pharmacokinetic variability
The concentration-time profile, clinical information, and
pharmacokinetic parameters for two of the patients who
provided samples on multiple days are shown in Figure 4.
Much day-to-day variability in antibiotic pharmacokinet-




In this multicenter pharmacokinetic study of four antibi-
otics and tazobactam, the prescribed intensity of CRRT
did not adequately predict CLHDF or Sd, CLs, Vd, or half-
life. This did not appear to be explained by the age of theFigure 1 Marked variability but negative association between the sat
(non-significant) and CRRT effluent flow rate. Urea: Pearson r = −0.2016
P = 0.0704, n = 103 pairs. CRRT, continuous renal replacement therapy.filter, hematocrit, or serum albumin concentration. A
correlation was noted between antibiotic concentration in
the effluent and pre-filter plasma samples, where the efflu-
ent concentration was lower than that of plasma. Using
urea and creatinine as biomarkers of membrane function,
despite a correlation between effluent flow and CLHDF, we
detected failure of equilibration between dialysate and
plasma during higher CRRT intensity. The correlation
between the Sd of urea or creatinine with antibiotics was
inconsistent, limiting their role as a surrogate measures
for clearance.
Principles of extracorporeal solute removal
The influence of components of the prescription of an
extracorporeal treatment was recently reviewed [38]. In
the context of CRRT, effluent flow is the rate-limiting
step because it is slower than blood flow, so clearance is
anticipated to positively correlate with effluent flow rate.
Furthermore, clearance by convection is dose-dependent
and this is the most efficient method of removing larger
molecules. Smaller molecules are also removed efficiently
by diffusion; however, the effect of diffusion is non-linearuration coefficients (Sd) of urea (significant) and creatinine
, P = 0.0383, r2 = 0.04063, n = 106 pairs; creatinine: Pearson r = −0.1790,
Figure 2 Positive correlation between the saturation coefficient (Sd) of vancomycin with both urea and creatinine. Urea: Spearman
r = 0.3817, P = 0.0074, n = 48 pairs; creatinine: Spearman r = 0.5297, P = 0.0001, n = 48 pairs.
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clearance. Post-filter replacement maximizes removal but
this may be at the expense of the life of the filter [39].
Our results suggest that these simple and logical rela-
tionships may not be observed in clinical practice. In
particular, in our study, the effect of prescribed CRRT
effluent flow rate on antibiotic clearance was not con-
sistently dose-dependent. Others have reported similar
findings, including a higher Sd for beta-2 microglobulin
(MW 11,000) with increasing ultrafiltration rates, and
have observed that varying the proportion of dialysate
and ultrafiltrate flows in hemodiafiltration influences the
Sd of different solutes variably [40].
Factors that may interfere with extracorporeal solute removal
A correlation was noted between CLHDF and effluent
flow for vancomycin, creatinine, and urea but not for
other antibiotics. These observations, coupled with the
decrease in the Sd of urea with increasing effluent flow,
indicate that equilibration across the filter is unpredict-
able and may decrease at higher effluent flow rates.Table 2 Calculated systemic pharmacokinetic parameters for
compared with values reported for critically ill patients in the
Population estimate in this
study (and range in individuals)
Random
effects – BSV (CV%)
CL, mL/minute Vd BSVCL BSVVd
Ciprofloxacin 58 (53-63) 37.7 L 10.0 34.6
(0.32-0.88 L/kg)
Meropenem 38 (23-95) 17.5 L 34.5 37.8
(0.14-0.61 L/kg)
Piperacillin 59 (37-115) 18.7 L 40.9 27.2
(0.14-0.29 L/kg)
Tazobactam 113 (45-248) 49.3 L 52.3 34.5
(0.54-0.55 L/kg)
Vancomycin 25 (16-33) 39.7 L 27.4 24.9
(0.32-0.74 L/kg)
aCalculated on the basis of the mean body weight reported in the study or using 7
of variation; RUV, residual unexplained variability; SD, standard deviation; Vd, volumThis implies a dynamic but unpredictable loss of filter
membrane function with use and this loss may be due to
partial filter clotting or membrane fouling due to higher
transmembrane pressures [41,42]. Smaller molecules
may be more affected by this process because their clear-
ance is diffusion-dependent [40]. The age of the filter
probably failed to have an influence in our study because
of selection bias (filters that are better functioning and
less prone to clotting will last longer). Finally, even in
laboratory-based testing of dialyzers, there is marked
scatter of these data because of any of the above-
mentioned factors and changes in transit time due to the
effect of internal and back filtration of solutes or water
or both [43]. Adsorption of antibiotic to the filter may
also contribute to the results observed.
Influence of continuous renal replacement therapy on
clearances
The extracorporeal antibiotic and tazobactam CLs observed
are consistent with data in the literature [12]; however, we
also noted a wide dispersion of results within a singleantibiotics and tazobactam assessed in this study
literature
Random error Values reported
in the literature
RUV (CV%) SD, mg/L CL, mL/minutea Vd, La
- 0.99 34-617 [16-18] 28-224 [16-18]
16.8 2.07 23-236 [10,19-27] 12-212 [10,19-27]
44 - 24-438 [10,21,28-34] 10-120 [10,21,28-34]
41 - 22-180 [28-30,32,34] 8-60 [28-30,32,34]
16 0.032 23-73 [35-37] 20-137 [35-37]
0 kg, if required. BSV, between-subject variability; CL, clearance; CV, coefficient
e of distribution.



























Figure 3 Marked inter-individual and inter-occasion variability
in the plasma concentration-time profile of meropenem over
12 hours following 17 doses of either 500 or 1,000 mg to 12
patients. Simulated concentration-time profiles using a single
compartment equation are based on the trough concentration,
time of infusion, and calculated systemic clearance and volume of
distribution for each occasion (performed by using GraphPad Prism
version 4.03 for Windows; GraphPad Software, San Diego, CA, USA).
a
b
Figure 4 Examples of inter-occasion variability in antibiotic
pharmacokinetics. (a) Admission to the intensive care unit (ICU) after
coronary artery bypass grafts and valve repair, requiring mechanical
ventilation and vasopressors for hypotension (not attributed to sepsis).
This patient received higher-intensity continuous renal replacement
therapy (CRRT) and did not survive to hospital discharge. Meropenem
(1 g) was administered on each occasion. (b) Admission to the ICU from
the emergency department and subsequently diagnosis with Klebsiella
sepsis associated with a soft tissue infection, complicated by edema and
hypoalbuminemia (24 g/L). Treatment included mechanical ventilation,
antibiotics, and dopamine infusion (decreasing requirements during
admission, not required at the time of second samples). This patient
received higher-intensity CRRT and was alive at 90 days post-admission.
Ciprofloxacin (200 mg) was administered on both occasions. CL,
clearance; Vd, volume of distribution.
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clinical and statistical significance of the relatively small
differences in concentration that were observed between
groups. The reason for this variability requires further
investigation and may include differences in renal (and
residual function in patients with AKI) and non-renal
clearance mechanisms.
The CRRT regimen used in this study was that of
hemodiafiltration. In both types of CRRT, only the free
(unbound) antibiotic can be cleared. The antibiotics
assessed in this study are minimally protein-bound [44]:
ciprofloxacin 30% to 40%, meropenem 8%, piperacillin
20-30%, vancomycin 30% to 40%, and tazobactam 20% to
30% (although these values may change in critical illness
[26]); so vancomycin CL is predicted to be less than
meropenem. Differences in MW can also influence CL in
certain CRRT regimens. For example, the partial diffusive
CL used in continuous veno-venous hemodiafiltration will
only achieve less vancomycin removal than meropenem;
however, we noted inconsistencies in this simple assump-
tion, and possible reasons were discussed above.
Relationship to previous studies
We observed both inter-individual and inter-occasion
(intra-individual) variability in pharmacokinetics. Some
variability may depend on the clinical characteristics of
patients. For example, in sepsis and critical illness,
ciprofloxacin CL and Vd are decreased compared with
volunteers matched for creatinine CL and weight [18].
Similarly, the Vd and CL of meropenem are lower in crit-
ically ill patients with sepsis compared with those with
multitrauma, matched for creatinine CL [22]. Finally, the
calculated CL and Vd for piperacillin is lower aftermultiple doses administered (similar to the context of our
data [9]) compared with a single dose [31]. Dynamic
changes in residual renal function may specifically con-
tribute to these observations.
Observations with piperacillin and tazobactam
Piperacillin and tazobactam are co-formulated, and so
assessment of their individual pharmacokinetics may
inform dosage recommendations. Between-subject vari-
ation in pharmacokinetics was observed (Table 2), but
with tazobactam there was little variability in the weight-
normalized Vd of tazobactam. This suggests that its Vd
was influenced primarily by body weight rather than the
pathophysiology of critical illness. The CL and Vd of
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studies have shown a similar relationship [28,30] but
others have not [29]. Some studies have quantified
piperacillin pharmacokinetics and extrapolated these
directly to those of tazobactam [10,21], but this appears
to be reliable. We noted marked variability in the ratio
of piperacillin to tazobactam plasma concentrations as
reported by others [28].
Contribution of extracorporeal clearance to the total
antibiotic clearance
Systemic CL and elimination half-life did not differ
according to CRRT dose, and so the CRRT prescription
may not be useful for guiding antibiotic prescribing. This
has been observed previously [10,22,26]. There is signifi-
cant non-renal clearance of vancomycin early in the
course of AKI, but this decreases with time [45], which
may also contribute to the poor relationship. The contri-
bution of extracorporeal CL to systemic CL was variable.
This related to the combined effect of the variability in
extracorporeal CL and inter-individual and inter-occasion
(despite identical CRRT regimens) variability in systemic
pharmacokinetics. In many cases, extracorporeal CL
accounted for more than 30% of the observed systemic
CL for that antibiotic, which is a suggested threshold
for adjustment of the dosing regimen. Such variability
in CL limits attempts to develop dosing guidelines.
Of note, CLHDF appeared to exceed CLs in some cases.
The reason for this is not apparent from our data but may
relate to an error with either of these calculated values. For
example, it has been noted that the delivered effluent flow
rate is frequently lower than the prescribed flow rate, and
so the calculation of clearance based on the prescribed
effluent rate may overstate the actual clearance [41].
Strengths and limitations
We evaluated the pharmacokinetics of multiple clinically
relevant antibiotics administered to patients as part of a
prospective multicenter observational study within a large
randomized controlled trial. Multiple measurements were
obtained, and similarities were observed between our data
and the literature. Our data, however, greatly expand our
understanding of CL, Vd, and pharmacokinetics in the set-
ting of CRRT treatment using different CRRT doses and
the advantages of randomization and multiple sampling.
Although median extracorporeal CL values were con-
sistent with the literature, the degree of variability was
an unexpected finding. All care was taken with the
collection of samples by designated staff, subsequent
storage, and then analysis using validated methods. How-
ever, we cannot exclude that this reflected unmeasured or
unknown clinical or mechanical factors occurring during
CRRT (for example, an undetected machine error at the
time of sampling or a difference between the prescribedand delivered effluent flow rate); however, this also reflects
clinical reality. The impact of these factors may have been
reduced if clearance was determined from a prolonged
collection (over hours) rather than at a point in time, as
used in our study.
Our study might be underpowered to detect a true
difference in clearance on the basis of CRRT intensity,
relating in part, to the selection of patients. The dose
ratio of lower- to higher-intensity CRRT effluent is 0.60
per protocol, but in this study the ratio was 0.76 based
on the achieved median effluent flow rates. This may
narrow the difference between the two groups, although
this effect would be lessened by analysis in terms of the
actual effluent production rate as performed here rather
than according to milliliters per kilogram.
Conclusions
We have identified marked variability in systemic CL
and Vd of multiple antibiotics in critically ill patients
with AKI and also the variable influence of CRRT regimen
on extracorporeal CL. Taken together, such variability
complicates empiric antibiotic prescribing during CRRT.
Ongoing research to further explore what factors contrib-
ute to this variability is important. In the meantime,
drug monitoring may be the most practical method for
ensuring that antibiotic therapeutic targets are achieved
in critically ill patients receiving CRRT.
Key messages
 In this multicenter pharmacokinetic study, the
prescribed intensity of continuous renal replacement
therapy (CRRT) did not adequately predict solute
clearance, volume of distribution, half-life, or the
saturation coefficient. This did not appear to be
explained by the age of the filter, hematocrit, or
serum albumin concentration.
 Using urea and creatinine as biomarkers of membrane
function, despite a correlation between effluent flow
and clearance from hemodiafiltration (CLHDF), we
detected failure of equilibration between dialysate and
plasma during higher CRRT intensity.
 The correlation between the saturation coefficient of
urea or creatinine with antibiotics was inconsistent,
limiting their role as a surrogate measures for
clearance.
 This variable pharmacokinetics complicates empiric
antibiotic prescribing during CRRT, and ongoing
research is required to determine factors that
contribute to this variability.
 In the meantime, drug monitoring may be the most
practical method for ensuring that antibiotic
therapeutic targets are achieved in critically ill patients
receiving CRRT.
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